Total Payments
$762,544
2024 Payments
$15,796
Companies
36
Transactions
1,189
Medicare Patients
6,264
Medicare Billing
$11.1M
Payment Breakdown by Category
Other$569,719 (74.7%)
Travel$98,562 (12.9%)
Consulting$61,201 (8.0%)
Food & Beverage$25,957 (3.4%)
Research$6,912 (0.9%)
Education$192.67 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $544,712 | 226 | 71.4% |
| Travel and Lodging | $98,562 | 224 | 12.9% |
| Consulting Fee | $61,201 | 25 | 8.0% |
| Food and Beverage | $25,957 | 693 | 3.4% |
| Honoraria | $25,008 | 7 | 3.3% |
| Unspecified | $6,912 | 2 | 0.9% |
| Education | $192.67 | 12 | 0.0% |
Payments by Type
General
$755,632
1,187 transactions
Research
$6,912
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $287,739 | 227 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $117,474 | 157 | $0 (2024) |
| Lilly USA, LLC | $114,217 | 210 | $0 (2023) |
| GlaxoSmithKline, LLC. | $79,511 | 73 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $40,273 | 96 | $0 (2024) |
| ABBVIE INC. | $39,492 | 146 | $0 (2024) |
| Amgen Inc. | $30,104 | 72 | $0 (2024) |
| Horizon Pharma plc | $22,318 | 29 | $0 (2018) |
| Horizon Therapeutics plc | $7,272 | 32 | $0 (2023) |
| Eli Lilly Export S.A. Puerto Rico Branch | $6,688 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $15,796 | 75 | GlaxoSmithKline, LLC. ($13,345) |
| 2023 | $48,628 | 86 | GlaxoSmithKline, LLC. ($30,214) |
| 2022 | $69,198 | 136 | GlaxoSmithKline, LLC. ($24,290) |
| 2021 | $23,156 | 52 | GlaxoSmithKline, LLC. ($8,835) |
| 2020 | $67,335 | 102 | Amgen Inc. ($25,050) |
| 2019 | $164,061 | 255 | Celgene Corporation ($63,207) |
| 2018 | $230,852 | 310 | Celgene Corporation ($117,119) |
| 2017 | $143,517 | 173 | Celgene Corporation ($107,413) |
All Payment Transactions
1,189 individual payment records from CMS Open Payments — Page 1 of 48
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $15.88 | General |
| Category: Dermatology | ||||||
| 12/17/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $10.80 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/12/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $6.51 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $9.27 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/04/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $8.94 | General |
| Category: IMMUNOLOGY | ||||||
| 12/02/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $7.81 | General |
| Category: Bone Health | ||||||
| 11/27/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $27.26 | General |
| Category: Immunology | ||||||
| 11/20/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $8.50 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: Dermatology | ||||||
| 11/17/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $126.53 | General |
| Category: Dermatology | ||||||
| 11/17/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $67.84 | General |
| Category: Rheumatology | ||||||
| 11/12/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $41.48 | General |
| Category: Immunology | ||||||
| 11/05/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $14.79 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 11/04/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $9.22 | General |
| Category: IMMUNOLOGY | ||||||
| 11/01/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $8.35 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/31/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $7.87 | General |
| Category: Dermatology | ||||||
| 10/28/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/27/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological), NUCALA | Food and Beverage | In-kind items and services | $25.08 | General |
| Category: IMMUNOLOGY | ||||||
| 10/21/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/17/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Travel and Lodging | Cash or cash equivalent | $83.88 | General |
| Category: IMMUNOLOGY | ||||||
| 10/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $25.15 | General |
| Category: RESPIRATORY | ||||||
| 10/09/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Travel and Lodging | Cash or cash equivalent | $143.05 | General |
| Category: IMMUNOLOGY | ||||||
| 10/09/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $7.80 | General |
| Category: IMMUNOLOGY | ||||||
| 10/03/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $121.84 | General |
| Category: IMMUNOLOGY | ||||||
| 10/01/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $17.55 | General |
| Category: Dermatology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LY3337641 IN ADULT SUBJECTS WITH RHEUMATOID ARTHRITIS: THE RAJUVENATE STUDY | Eli Lilly Export S.A. Puerto Rico Branch | $6,688 | 1 |
| A MULTICENTER LONG-TERM EXTENSION STUDY OF 104 WEEKS INCLUDING A DOUBLE BLIND PLACEBO CONTROLLED 40 WEEK RANDOMIZED WITHDRAWAL RETREATMENT PERIOD TO EVALUATE THE MAINTENANCE OF TREATMENT EFFECT OF IXEKIZUMAB LY2439821 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS | Eli Lilly and Company | $223.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 1,436 | 223,755 | $6.2M | $1.9M |
| 2022 | 22 | 1,496 | 262,667 | $9.5M | $2.4M |
| 2021 | 23 | 1,581 | 279,010 | $10.9M | $3.1M |
| 2020 | 24 | 1,751 | 282,347 | $11.8M | $3.8M |
Total Patients
6,264
Total Services
1,047,779
Medicare Billing
$11.1M
Procedure Codes
90
All Medicare Procedures & Services
90 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 33 | 150,080 | $2.7M | $698,089 | 26.1% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 50 | 44,300 | $1.7M | $465,261 | 27.3% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 12 | 7,000 | $504,000 | $230,586 | 45.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 88 | 9,180 | $367,200 | $167,573 | 45.6% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 11 | 9,870 | $169,172 | $78,845 | 46.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 134 | 738 | $295,200 | $67,147 | 22.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 431 | 730 | $175,940 | $65,015 | 37.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 172 | 250 | $80,325 | $31,425 | 39.1% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 108 | 439 | $72,435 | $22,253 | 30.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 75 | 97 | $15,730 | $5,945 | 37.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 31 | 31 | $12,152 | $4,813 | 39.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 53 | 86 | $34,400 | $4,062 | 11.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 32 | 168 | $16,800 | $3,409 | 20.3% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 32 | 310 | $31,000 | $2,950 | 9.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 22 | 22 | $7,008 | $2,675 | 38.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 63 | 142 | $5,680 | $1,504 | 26.5% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 12 | 18 | $2,592 | $868.17 | 33.5% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 22 | 78 | $400.00 | $303.17 | 75.8% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 32 | 163 | $815.00 | $81.46 | 10.0% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 12 | 14 | $210.00 | $77.70 | 37.0% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 11 | 39 | $151.00 | $40.29 | 26.7% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2022 | 37 | 148,000 | $3.6M | $680,519 | 19.2% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 48 | 41,200 | $2.1M | $486,195 | 23.6% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 18 | 10,275 | $739,800 | $356,193 | 48.1% |
| J9312 | Injection, rituximab, 10 mg | Office | 2022 | 16 | 3,800 | $722,000 | $254,598 | 35.3% |
About Dr. Joseph Shanahan, MD
Dr. Joseph Shanahan, MD is a Rheumatology healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1043394901.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Shanahan, MD has received a total of $762,544 in payments from pharmaceutical and medical device companies, with $15,796 received in 2024. These payments were reported across 1,189 transactions from 36 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($544,712).
As a Medicare-enrolled provider, Shanahan has provided services to 6,264 Medicare beneficiaries, totaling 1,047,779 services with total Medicare billing of $11.1M. Data is available for 4 years (2020–2023), covering 90 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Durham, NC
- Active Since 10/25/2006
- Last Updated 11/07/2024
- Taxonomy Code 207RR0500X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1043394901
Products in Payments
- Otezla (Drug) $312,321
- COSENTYX (Biological) $86,536
- TALTZ (Drug) $86,354
- BENLYSTA (Biological) $79,471
- KEVZARA SARILUMAB INJECTION (Biological) $27,695
- KRYSTEXXA (Drug) $22,268
- KEVZARA (Biological) $12,745
- RINVOQ (Drug) $10,552
- Rinvoq (Biological) $10,238
- SKYRIZI (Biological) $8,860
- KRYSTEXXA (Biological) $7,363
- RINVOQ (Biological) $6,904
- OLUMIANT (Drug) $6,525
- Otezla (Biological) $4,367
- KEVZARA (Drug) $3,878
- TREMFYA (Drug) $3,091
- Humira (Biological) $2,783
- OFEV (Drug) $1,696
- ILARIS (Biological) $1,612
- COSENTYX (Drug) $626.52
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Durham
Ralph Snyderman, M.d, M.D
Rheumatology — Payments: $1.7M
Rheumatology $1.7M
Virginia Kraus
Rheumatology — Payments: $500,154
Rheumatology $500,154
Megan Clowse
Rheumatology — Payments: $137,567
Rheumatology $137,567
Laura Schanberg, M.d, M.D
Rheumatology — Payments: $42,792
Rheumatology $42,792
Tony Ning, Md, MD
Rheumatology — Payments: $15,743
Rheumatology $15,743
Dr. Consuelo Rabinovich, M.d, M.D
Rheumatology — Payments: $6,119
Rheumatology $6,119